Autism is a life-long disability that as of today neither have a biological- based clinical diagnostics not an effective pharmacological treatment. Point6 Bio is a computational biology company focused on capturing multi-omics molecular insights from the proteome including from subject’s gut microbiome, to identify biomarker signatures, which will eventually affect treatment decision and new drug targets identification in Autism.
Circuit-Bio is a synthetic biology company developing a unique platform of logical gene circuits for cancer immunotherapy. The company’s platform focuses on generating gene circuits able to locally and accurately produce a combination of multiple immune-stimulating proteins (immunomodulators) exclusively expressed in targeted tumor cells. The circuit selectively converts cancer cells into ‘Trojan horses’ utilized as an anti-tumor resource that triggers a robust, long-term, anti-tumor immune response.The immunomodulators’ output is tightly controlled by two de novo synthetic cancer-specific promoters (SPECS) and specifically enhances a Boolean AND gate, which enables multi-output gene expression only when both synthetic promoters are activated simultaneously. This emerging bio-convergence approach differentiates itself from other immunotherapy treatments by a unique tunable mode of action and therefore can overcome some of the major obstacles arising from the treatment of immunotherapeutic drugs. The circuit modularity can be reflected by the ability to control and adapt each of the circuit components to the treated indication, such as selecting the most effective tumor-specific immunomodulator combination output.
Pupil assessment is a fundamental and crucial part of the neurological examination. It is a direct indication to brain stem condition, irregular pupillary response in brain injury cases is an indication that may require immediate clinical intervention. In spite of its clinical importance, pupillary examination is still conducted manually with a conventional light source. The Need is for an automatic pupil reflex monitoring; assessing neurological status of brain injured patients.
MyOR prevents a range of health issues using innovative, holistic solutions that combine predictive, noninvasive, monitoring technologies and customized products to help the body help itself. Our monitoring technologies leverage skin-sensing techniques and data science tools to gain new insight into systemic health and reveal the inner workings of your body. With these technologies in hand, MyOR customizes care solutions to prevent health conditions from developing.
LipoMedix is a development-stage privately held company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery. The Company was established in order to advance the pharmaceutical and clinical development of a patented new chemical entity prodrug of mitomycin-C and its efficient delivery in liposomes to cancer-affected target organs. This formulation known as Promitil – Pegylated Liposomal Mitomycin-C Prodrug (PL-MLP) – overcomes the problems associated with mitomycin-C toxicity and turn it into a state-of-the-art anti-cancer drug that will potentially become the therapy of choice in a variety of cancers, especially those derived from the gastrointestinal tract (stomach, pancreas, colorectal). The inventor and scientific founder, of LipoMedix is Prof. Alberto Gabizon of the Hebrew University – Shaare Zedek Medical Center who is also the co-inventor and co-developer of Doxil, (the first FDA-approved nano-drug in cancer therapy). As co-developer of Doxil® Prof. Gabizon is one of the few scientists intimately familiar with the successful development & commercialization process of liposomal drugs.